TSThaynara Ramalho Santos

Thaynara Ramalho Santos

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Thaynara Ramalho Santos has a total of 14 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Zinc Bismuthate-Based Nanocomposites: Promising Antimicro-Bial Properties for Biomedical Applications

    by Felipe Rodrigues Silva, Edson Tobias De Jesus, Mayara Coelho Sa, Margaret Dawson, Thaynara Ramalho Santos, Alan S. de Menezes, Clenilton C. dos Santos, Ulisses Magalhaes Nascimento, Erima Joyssielly Mendonça Castro, Rita de Cassia Mendonça de Miranda, et al.

    Background/Objectives: The growing threat of antimicrobial resistance (AMR) has inten-sified the search for innovative antimicrobial materials. Herein, we synthesized and characterized zinc bismuthate-based nanocomposites (ZB1 and ZB4) and investigated their antimicrobial efficacy against two Gram-positive bacteria (Staphylococcus aureus and Corynebacterium diphtheriae), one Gram-negative bacterium (Klebsiella pneumoniae), and two fungal pathogens (Cryptococcus neoformans and Candida albicans). Toxicity was further as-sessed using Tenebrio molitor larvae as an alternative model. Methods: Nanocomposites were prepared via a hydrothermal process and characterized using X-ray diffraction (XRD), Raman spectroscopy, Zeta potential, and high-resolution transmission electron microscopy (HR-TEM). Antimicrobial activity was evaluated through disk diffusion as-says coupled with minimum inhibitory concentration (MIC) and minimum fungicidal concentration (MFC) assessments. Results: ZB1 and ZB4 inhibited S. aureus (10.7 ± 1.2 mm and 11.3 ± 1.2 mm), C. diphtheriae (10.7 ± 1.1 mm and 11.3 ± 1.1 mm), and C. neoformans (10.7 ± 1.1 mm and 11.7 ± 2.9 mm), while no inhibition was observed for C. albicans and K. pneumoniae. From MIC and MFC evaluations, ZB1 was effective up to 1000 μg/mL, and ZB4 up to 500 μg/mL. Toxicity assays revealed survival rates of 70% for ZB1 and 60% for ZB4, with no statistically significant differences compared to the control (p = 0.156). Notably, ZB4 is a promising candidate due to its enhanced antimicrobial performance and moderate toxicity. Conclusions: Our findings highlight ZB1 and ZB4 nanocomposites as promising antimicrobial agents, offering new avenues in nanotechnology-driven healthcare solutions aimed at tackling antimicrobial resistance.